KDM4B and cancer: Two KDM enzymes, KDM3A and KDM4B, which remove transcriptionally repressive H3K9me1/me2 and H3K9me2/me3 marks, respectively, have both been associated with oncogenic roles in numerous cancer types, suggesting that perturbation of their activity may be efficacious as a therapeutic option [19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34].